Medivir (MVIR.ST) Stock Price

Medivir Price

OMX·CLOSED
1.45
​
Market closed

Revenue at Medivir has contracted by 13.3% per year over the past 19 years to 8.51 M SEK. Earnings per share have grown at 22.5% per year over the last 5 years. For Medivir, the net margin of -1,109.8% is down versus -247.2% a few years ago. The consensus 12-month price target for Medivir is 4.08 SEK, about 181.0% above where the stock trades today. Of 9 analysts, 0 rate the stock a buy — an overall Sell consensus.

Medivir stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Medivir business model & stock analysis

Medivir AB generates revenue by developing pharmaceutical products, specifically focusing on protease inhibitor design and nucleoside and nucleotide science to create therapies for cancers with unmet medical need. The company operates from its headquarters in Huddinge, Stockholm, and relies on a specialized team of nine full-time employees to drive its research and development efforts. The firm's financial model is supported by its clinical pipeline, which includes remetinostat, a topical histone deacetylase inhibitor currently in phase II clinical studies for cutaneous T-cell lymphoma. Additionally, the company is advancing birinapant in combination with Keytruda for solid tumors in phase I studies, MIV-818 for liver cancer in phase I trials, and MIV-711 for osteoarthritis in an IIa extension study. Beyond these specific assets, Medivir AB sustains its operations through additional research projects conducted in cooperation with other institutions. This collaborative approach complements its internal development programs and contributes to the overall value of its proprietary science and therapeutic candidates.

Frequently asked questions about Medivir

Analysts currently set an average price target of 4.08 SEK for the Medivir stock (median: 4.08 SEK), implying +210.0 % versus the latest price. The consensus is based on 9 analyst ratings.

9 analysts currently rate the Medivir stock: 0 recommend buying, 3 holding and 6 selling. For 2026, analysts expect Medivir to generate revenue of 4.60 M SEK and earnings per share of -0.12 SEK.

Converted at the current exchange rate, the Medivir share trades at 0.13 EUR (1.45 SEK).

The Medivir share (MVIR.ST) is listed on 5 stock exchanges, including: London (0GP7.L), Frankfurt (MVR0.F), München (MVR0.MU), Stockholm (MVIR.ST).

The expected revenue of Medivir is 4.60 M SEK. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Medivir is -53.84 M SEK. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Medivir is currently -12.10. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Medivir stock.

The price-to-sales ratio (P/S) of Medivir is currently 141.62. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Medivir stock.

The Eulerpool Quality Score for Medivir is 2/10.

The ISIN of Medivir is SE0020181014. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Medivir is A3EFZT. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Medivir is MVIR.ST. The ticker symbol is used to trade Medivir shares on the stock exchange.

Fair ValueTerminal
1.26 SEK
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Biotechnology
Number of shares
Employees
Revenue per Employee
945,111.11 SEK
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website medivir.se
Country
Sweden
Currency
SEK
Initial public offering
Feb 29, 1996
ISIN
SE0020181014
Cusip
W5S103238
Market capitalization
651.47 M SEKSmall Cap
52-Week Range
PEG
-0.11
P/E ratio
P/Ee 2026
-12.10
P/Ee 2027
-9.08
P/Ee 2028
-2.78
P/Ee 2029
—
P/Ee 2030
—
P/Se
141.62
EV/EBIT
—
P/B Ratio
2.46
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-35.69 %
Last updated Nov 12, 2026, 12:48 AM

Medivir Peer Group

Medivir Ticker

FRANKFURT · MVR0.FLONDON · 0GP7.LLONDON STOCK EXCHANGE · 0GP7.LMUNICH · MVR0.MUSTOCKHOLM · MVIR.ST

Medivir FIGI

MVIR:SS · BBG000HPVJQ1MVR0:GR · BBG000MJRMD1MVR0:GF · BBG000MJRNN8MVR0:GD · BBG000MJRPD4MVR0:GS · BBG000MJRQM2MVR0:GM · BBG000MJRR77MVR0:GB · BBG000MJRRW9MVIRB:EO · BBG000QRVC91MVIRB:XH · BBG000QRVDT7MVIRB:XC · BBG000QRVFN8MVIRB:XF · BBG000QRVG92MVIRB:XE · BBG000QRVJ05

All fundamentals and in-depth analysis of Medivir

Our stock analysis for Medivir stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Medivir. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.